Navigation Links
EntreMed Announces 2008 Corporate and Clinical Program Priorities
Date:3/13/2008

discovered and initially

developed by Roche; EntreMed has an exclusive worldwide license to

develop and commercialize the drug.

-- MKC-1 is currently in multiple Phase 1 and Phase 2 clinical trials,

including metastatic breast cancer (MBC), non-small cell lung cancer

(NSCLC), hematological cancers, ovarian and endometrial cancer, and

pancreatic cancer. Milestones for MKC-1 in 2008 include reporting

results for the single agent MKC-1 MBC study (2Q08); presentation of

interim data for MKC-1/Alimta combination study in NSCLC (2Q08);

presentation of Phase 1 data for MKC-1 in hematological cancers (2H08);

initiation of a Phase 1 MKC-1 continuous dosing study (2Q08); and

presentation of interim data for a Phase 2 study in pancreatic cancer

(4Q08).

-- ENMD-1198 is a potent, orally-active, antimitotic agent discovered at

EntreMed that causes cell cycle arrest and apoptosis in tumor cells.

ENMD-1198 has shown pronounced antitumor activity and survival

increases in multiple preclinical models, including a substantial

decrease in tumor cell proliferation and angiogenesis in a breast

cancer model; synergistic effects in combination with vincristine that

prolonged survival in preclinical leukemia models; and a three-fold

increase in survival compared to standard-of-care Cisplatin in a

preclinical NSCLC model.

-- A Phase 1b dose-escalation clinical trial is currently underway to

evaluate ENMD-1198 in patients with refractory solid tumors. Completion

of the study is expected around mid-2008 with a further trial expected

in the second half of 2008. ENMD-1198 milestones for 2008 include

completion of Phase 1b enrollment (2Q/3Q08); initiation of an expanded

Phase 1 or Phase 2 trial (3Q/4Q08); and the reporting of data for the

Phase 1b clinical
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
2. EntreMed to Present at BIO CEO and Investor Conference
3. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
4. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
5. EntreMed Appoints Senior Vice President of Research and Development
6. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
7. Arpida Announces Full Year 2007 Financial Results
8. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
9. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
10. Exelixis Announces March 17 Webcast of Presentation at the Cowen and Company Annual Health Care Conference
11. deCODE Genetics Announces Full-year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... May 05, 2015 Synedgen Inc. is ... as Regulatory Affairs Manager. , Dr. Nguyen brings to ... juncture for the company as it moves forward in ... over the next two years. Dr. Nguyen will lead ... the regulatory key documents that must be completed in ...
(Date:5/5/2015)... MA (PRWEB) May 05, 2015 The ... ), a Massachusetts-based non-profit operating in the public interest, ... affiliate of the Hearst Communications Company, have formed a ... for public outreach and education across the healthcare and ... for the voice of patients and the public to ...
(Date:5/4/2015)... Many of us take a healthy ... with rare, inherited mutations of certain genes, severe ... impaired immune responses. Now, researchers at ... role for calcium signaling in immune responses to ... causing tuberculosis (TB). Specifically, they ...
(Date:5/4/2015)... , May 4, 2015 Tobira Therapeutics, ... on the development and commercialization of novel treatments ... completion of its merger with Regado Biosciences, Inc. ... the closing of the merger, Tobira raised $40 ... new investors and all current Tobira institutional investors, ...
Breaking Biology Technology:Synedgen Announces the Appointment of Regulatory Affairs Manager 2ACRES and San Antonio Express-News Launch Blog on Accountability in Clinical Research 2ACRES and San Antonio Express-News Launch Blog on Accountability in Clinical Research 3ACRES and San Antonio Express-News Launch Blog on Accountability in Clinical Research 4Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 2Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 3Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 2Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 3Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 4Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 5Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 6
... Here are some troubleshooting hints that we have gathered , if your PCR yields no product:, , , ... , , , ... , , , ... , , , ...
... , , , , , Here are some troubleshooting hints that we have gathered , ... , , , ... , , , ... , , , , ...
... , , , , from rat lung, recombinant, , , , ... Catalog Number, Pack Size, , ... , , 3335402, ... , , , , , Package Inserts/Product , Instructions, ...
Cached Biology Technology:Trouble-shooting: No product 2Trouble-shooting: No product 3Trouble-shooting: No product 4Trouble-shooting: No product 5Trouble-shooting: Non-specific bands 2Trouble-shooting: Non-specific bands 3Trouble-shooting: Non-specific bands 4Trouble-shooting: Non-specific bands 5Trouble-shooting: Non-specific bands 6
(Date:4/27/2015)... , April 27, 2015  For more than four ... show has been the premier worldwide event for the ... is a must-attend event for any local, national, or ... the emerging commercial markets and current applications of unmanned ... of this projected $48 billion industry, and how it ...
(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
(Date:4/27/2015)... FORT LAUDERDALE, Fla. , Apr. 27, 2015 /PRNewswire/ ... provider of access control and security systems is pleased ... joined the company as a consultant and member of ... Bedore is widely known as a thought leader ... Socrates Distance Learning Technology Group, and has published studies ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... , This release is available in German ... area of climate research: for decades, scientists have been asking ... dust particles suspended in the atmosphere, enlarge the cloud cover ... no progress on this issue. Two scientists from the Max ...
... a major milestone in its three years of operation, RadMD ... for 150 clinical trials. , The most recent trial, ... was designed to test the efficacy of a new treatment ... support the primary analysis of Progression Free Survival based on ...
... scientists have received grants from the latest round of ... Recovery and Reinvestment Act (ARRA) of 2009. To date, ... million. The recent round of funding includes three highly ... the Challenge Grant competition ― only about 500 were ...
Cached Biology News:Do dust particles curb climate change? 2Do dust particles curb climate change? 3Do dust particles curb climate change? 4RadMD reaches 150th clinical trial 2Forsyth receives highly competitive challenge grants 2
... BMP2 BMP2 belongs to the ... Bone morphogenic protein induces bone formation. ... the autosomal dominant disease of fibrodysplasia ... Synthetic peptide: PSDEVLSEFELRLLSM conjugated to ...
...
... is the successor to the original DS-U1. The ... the cameras in the Nikon DS camera line ... The DS-U2 transmits information at high speed, and ... hub and mass storage USB 2.0 interfaces. The ...
This unique buffer provides a gentle method for removal of primary and secondary antibodies to allow several reprobings on the same membrane. Gentle buffer will not alter the antigen for subsequent i...
Biology Products: